| Dear Voornaam
Weve just launched a pilot award to encourage multi-disciplinary research to develop new, scalable and generalised data solutions to common challenges in cancers that affect 0-24 year olds and advance our understanding of these cancers, their detection and treatment.
The Data for Childrens and Young Peoples Cancer Research Pilot Award offers up to 250k to support studies from a range of research areas including cancer biology, engineering and physics. Applicants may be from any career stage, from early-career to established senior researchers, and applications are open until 5 December 2023.
Find out more about the award and how to apply. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
CONGRATULATIONS TO OUR NEWEST GRANT AWARDEES Congratulations to the latest cohort of grant awardees, selected by our Clinical Research Committee in the July funding round.
Gordon Jayson and Richard Adams were awarded a Clinical Trial Award, and Michael Schmid, Paula Ghaneh, Ainhoa Mielgo and Daniel Palmer received our first Clinical Trial Award with a pre-clinical package.
Anna Wilkins, Emma Hall, Ann Henry, Finbar Slevin, Alexandra Clipson, Christopher Williams and Andrew Beggs were awarded Prospective Sample Collection Awards.
Follow us on social media to celebrate our new grant holders with the hashtag #CRUKFunded. |
|
|---|
|
|---|
|
|
 BROADENING HORIZONS: EMPOWER YOUR EARLY-CAREER JOURNEY Applications to the mentoring programme, Broadening Horizons, are now open. This nine-month cross-sector initiative is expertly designed to empower early-career researchers with a passion for translational research.
Broadening Horizons is delivered by Moving Ahead and funded by Wellcome and our innovation arm, Cancer Research Horizons. Since its inception in 2020, it has supported 200 participants. Apply now to join the third cohort in January 2024 and gain invaluable support for your personal and professional development. |
|
|---|
|  STAY UP TO DATE WITH ENTREPRENEURIAL OPPORTUNITIES Are you interested in drug translation or spinning out a company? Do you have an innovation you are working on?
If so, make sure to sign up to the Cancer Research Horizons monthly newsletter to be the first to hear about its development and accelerator programmes, funding opportunities, and the latest updates in the world of therapeutic innovation. |
|
|---|
|
|---|
|
|
MATTHEW HOARE: EXPANDING WHAT WE KNOW ABOUT LIVER CANCER Matt Hoare, Group Leader at the University of Cambridge Early Cancer Institute, is working to decode the cancerisation field effect in chronic liver disease.
We caught up with him to talk about early detection, senescence and why you need to pay attention to the increasing prevalence of metabolic disorders. |
|
|---|
|
|---|
|
|
REGISTER FOR PARIS CONFERENCE FOR AN INTERNATIONAL CHILDHOOD CANCER DATA PARTNERSHIP Paediatric cancers encompass a wide range of rare diseases, with no single country having enough data to conduct the depth and breadth of research needed in these rare and ultra-rare tumours.
The International Childhood Cancer Data Partnership initiative is designed to bridge this gap, bringing together countries with a readiness to share high-quality data to answer critical research questions.
Its conference in Paris on 7-8 November will focus on global solutions to sharing clinical and demographic data and will host thematic workshops on data harmonisation, interoperability, governance and management.
Jointly hosted by the French National Cancer Institute and the National Cancer Institute of the United States, the conference is part of the recently established G7 Cancer Alliance. |
|
|---|
|
|---|
|
|
THE NEW DRUG CLASS THAT NEARLY WASNT Earlier this year we celebrated the positive results from the Phase 1 trial of MOv18, the first IgE antibody to enter clinical development. Compared to the IgG antibodies that are currently approved to treat cancer, this new class of drug has the potential to target tumours more efficiently and with higher potency.
However, this landmark treatment almost didnt make it into the clinic.
Nigel Blackburn, director of drug development at Cancer Research Horizons since 2009, reflects on the many hurdles that MOv18 had to leap to get to this point, and how the Centre for Drug Development was uniquely placed to steer it through its stuttering start. |
|
|---|
|
|---|
|
|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | Liverpool, UK 18 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 20 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 03 November 2023 |
|
|---|
|
|---|
| | | Edinburgh, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
